113 related articles for article (PubMed ID: 7808027)
1. Breast cancer and fenretinide, an analogue of vitamin A.
Cobleigh MA
Leukemia; 1994; 8 Suppl 3():S59-63. PubMed ID: 7808027
[TBL] [Abstract][Full Text] [Related]
2. Synthetic retinoid fenretinide in breast cancer chemoprevention.
Bonanni B; Lazzeroni M; Veronesi U
Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
[TBL] [Abstract][Full Text] [Related]
3. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
4. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials with retinoids for breast cancer chemoprevention.
Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
[TBL] [Abstract][Full Text] [Related]
6. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.
Guerrieri-Gonzaga A; Robertson C; Bonanni B; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Formelli F; Intra M; Latronico A; Franchi D; Pelosi G; Johnson K; Decensi A
J Clin Oncol; 2006 Jan; 24(1):129-35. PubMed ID: 16382122
[TBL] [Abstract][Full Text] [Related]
8. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer.
Cobleigh MA; Dowlatshahi K; Deutsch TA; Mehta RG; Moon RC; Minn F; Benson AB; Rademaker AW; Ashenhurst JB; Wade JL
J Clin Oncol; 1993 Mar; 11(3):474-7. PubMed ID: 8445423
[TBL] [Abstract][Full Text] [Related]
10. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer with fenretinide.
Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
[TBL] [Abstract][Full Text] [Related]
15. Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies.
Sogno I; Venè R; Ferrari N; De Censi A; Imperatori A; Noonan DM; Tosetti F; Albini A
Crit Rev Oncol Hematol; 2010 Jul; 75(1):2-14. PubMed ID: 20034809
[TBL] [Abstract][Full Text] [Related]
16. Fenretinide and its relation to cancer.
Ulukaya E; Wood EJ
Cancer Treat Rev; 1999 Aug; 25(4):229-35. PubMed ID: 10448131
[TBL] [Abstract][Full Text] [Related]
17. Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide.
Pirkmaier A; Yuen K; Hendley J; O'Connell MJ; Germain D
Clin Cancer Res; 2003 May; 9(5):1877-84. PubMed ID: 12738746
[TBL] [Abstract][Full Text] [Related]
18. [Breakthrough in breast cancer chemoprevention].
Kahán Z; Thurzó L
Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
20. Progress in chemoprevention of breast cancer.
Serrano D; Perego E; Costa A; Decensi A
Crit Rev Oncol Hematol; 2004 Feb; 49(2):109-17. PubMed ID: 15012972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
